Long Term Follow-up of Persistent Pain, Sensory Disturbances and Lymphedema After Breast Cancer Treatment
This study is enrolling participants by invitation only.
Sponsor:
Rigshospitalet, Denmark
Collaborator:
Danish Cancer Society
Information provided by (Responsible Party):
Kenneth Geving Andersen, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier:
NCT01543711
First received: February 28, 2012
Last updated: March 2, 2012
Last verified: February 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Persistent pain, sensory disturbances, lymphedema and functional impairment are frequently occurring late effects of breast cancer treatment. The investigators have previously published data on 3253 women treated for breast cancer in Denmark in the period 2005-2006. Very few studies have examined how these late effects change in time. The aim of this study is to examine in a well defined patient population any change in the prevalence of persistent pain, sensory disturbances, lymphedema and functional impairment, as well as risk factor profile.
Condition |
---|
Breast Cancer Pain Post Operative Pain Lymphedema Neuropathy |
Study Type: | Observational |
Study Design: | Observational Model: Cohort Time Perspective: Cross-Sectional |
Official Title: | Long Term Follow-up of Persistent Pain, Sensory Disturbances and Lymphedema After Breast Cancer Treatment |
Resource links provided by NLM:
Further study details as provided by Rigshospitalet, Denmark:
Primary Outcome Measures:
- Prevalence of persistent pain [ Time Frame: 6-7 years post operative ] [ Designated as safety issue: No ]Prevalence of pain in the breast area, axilla, side of chest or arm, as a yes/no variable
- Prevalence of patients changing pain status from the 2008 survey [ Time Frame: 6-7 years ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Prevalence of sensory disturbance [ Time Frame: 6-7 years ] [ Designated as safety issue: No ]
- Prevalence of self reported lymphedma [ Time Frame: 6-7 years ] [ Designated as safety issue: No ]
- Prevalence of functional impairment [ Time Frame: 6-7 years ] [ Designated as safety issue: No ]
- Risk factors associated for persistent pain, sensory disturbances, lymphedema or functional impairment [ Time Frame: 6-7 years ] [ Designated as safety issue: No ]
- Prevalence of patients changing status of sensory disturbances and self reported lymphedma [ Time Frame: 6-7 years ] [ Designated as safety issue: No ]
- Risk factors associated to changing status of sensory disturbances and lymphedema [ Time Frame: 6-7 years post operative ] [ Designated as safety issue: No ]
Estimated Enrollment: | 2828 |
Study Start Date: | January 2012 |
Estimated Study Completion Date: | April 2012 |
Estimated Primary Completion Date: | April 2012 (Final data collection date for primary outcome measure) |
Groups/Cohorts |
---|
Breast cancer survivors
Women treated for breast cancer, without signs of recurrence or metastasis
|
Eligibility
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Study Population
Woman treated for breast cancer in Denmark 2005-2006, and participated in the study in 2008
Criteria
Inclusion Criteria:
- Diagnosed with primary breast cancer between 2005-2006
- Participated in a study in 2008
Exclusion Criteria:
- Recurrent or new primary cancer
- Metastatic cancer
- Reconstructive surgery
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01543711
Locations
Denmark | |
Rigshospitalet, Copenhagen University Hospital | |
Copenhagen, Denmark |
Sponsors and Collaborators
Rigshospitalet, Denmark
Danish Cancer Society
Investigators
Principal Investigator: | Kenneth Geving Andersen, MD | Rigshospitalet, Denmark |
More Information
Publications:
Keywords provided by Rigshospitalet, Denmark:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 17, 2012
Publications:
Responsible Party: | Kenneth Geving Andersen, MD, Rigshospitalet, Denmark |
ClinicalTrials.gov Identifier: | NCT01543711 History of Changes |
Other Study ID Numbers: | 2007-41-1530 |
Study First Received: | February 28, 2012 |
Last Updated: | March 2, 2012 |
Health Authority: | Denmark: National Board of Health |
Keywords provided by Rigshospitalet, Denmark:
Breast cancer persistent pain neuropathic pain lymphedema |
Additional relevant MeSH terms:
Breast Neoplasms Lymphedema Pain, Postoperative Sensation Disorders Neoplasms by Site Neoplasms Breast Diseases Skin Diseases |
Lymphatic Diseases Postoperative Complications Pathologic Processes Pain Signs and Symptoms Neurologic Manifestations Nervous System Diseases |
ClinicalTrials.gov processed this record on October 17, 2012